TrialScientific reports2024

PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4-10 ng/ml.

Jing Wen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.